Meet the members of the Neurology research team at Rochester Regional Health.Meet the Neurology Research Team
The Neuroscience Department at Rochester Regional Health is dedicated to providing the highest level of care for its patients. Clinical trials are fundamental for the discovery of new treatments and for developing evidence based medicine, which is considered the best medical care. Participating in clinical trials allows us to offer the latest, cutting edge treatment to our patients and gives them the opportunity to contribute to the improvement of care for future patients. To pursue the goal of developing and providing the highest level of care, our research team is recruiting patients for the listed clinical multi-center trials.
Principal Investigator: Kelly Matmati, M.Sc., MD
Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, is a prospective, randomized, double-blind, multicenter trial with the primary null hypothesis that, in patients with TIA or minor ischemic stroke treated with aspirin 50-325 mg/day, there is no difference in the event-free survival at 90 days in those treated with clopidogrel (600 mg loading dose then 75 mg/day) compared to placebo when subjects are randomized within 12 hours of time last known free of new ischemic symptoms.
Continued uncertainty exists over benefits of early intensive blood pressure (BP) lowering in acute intracerebral hemorrhage (ICH), related to the non-significant primary outcomes, patient selection, and discordant results of INTERACT2 and ATACH-II. We designed INTERACT3 to determine the effectiveness of a goal-directed care bundle of active management (intensive BP lowering, glycemic control, treatment of pyrexia and reversal of anticoagulation) vs. usual care in ICH.